



## EP300 gene

E1A binding protein p300

### Normal Function

The *EP300* gene provides instructions for making a protein called p300. This protein regulates the activity of many genes in tissues throughout the body. It plays an essential role in controlling cell growth and division and prompting cells to mature and assume specialized functions (differentiate). The p300 protein appears to be critical for normal development before and after birth.

The p300 protein carries out its function by activating transcription, the process of making a blueprint of a gene for protein production. Specifically, p300 connects transcription factors, which are proteins that start the transcription process, with the complex of proteins that carries out transcription. On the basis of this function, p300 is called a transcriptional coactivator.

### Health Conditions Related to Genetic Changes

#### Rubinstein-Taybi syndrome

Several mutations in the *EP300* gene have been identified in people with Rubinstein-Taybi syndrome. These genetic changes are responsible for a small percentage of cases of this condition. Some mutations lead to the production of an abnormally small, nonfunctional version of the p300 protein, while other mutations prevent one copy of the gene from making any protein at all. These genetic changes all result in the loss of one functional copy of the *EP300* gene in each cell, which reduces the amount of p300 protein by half. Although researchers are uncertain how a reduction in the amount of this protein leads to the specific features of Rubinstein-Taybi syndrome, it is clear that the loss of one copy of the *EP300* gene disrupts normal development before and after birth.

#### Prostate cancer

#### Cancers

Rarely, chromosomal rearrangements (translocations) involving chromosome 22 have been associated with certain types of cancer. These genetic changes are somatic, which means they are acquired during a person's lifetime and are present only in certain cells. In cancer cells, translocations can disrupt the region of chromosome 22 that contains the *EP300* gene. For example, researchers have found a translocation between chromosome 8 and chromosome 22 in several people with a cancer of blood-forming cells called acute myeloid leukemia (AML). Another


translocation, involving chromosomes 11 and 22, has been found in a small number of people who have undergone cancer treatment. This chromosomal change is associated with the development of AML following chemotherapy for other forms of cancer.

Somatic mutations in the *EP300* gene have been identified in several other types of cancer. These mutations prevent the gene from producing any functional protein. Cells without the p300 protein cannot effectively restrain growth and division, allowing cancerous tumors to develop and grow. Somatic mutations in the *EP300* gene have been found in a small number of solid tumors, including cancers of the colon and rectum, stomach, breast, and pancreas. Studies suggest that *EP300* mutations may also play a role in the development of some prostate cancers. These genetic changes could help predict whether prostate tumors will increase in size or spread to other parts of the body.

### Chromosomal Location

Cytogenetic Location: 22q13.2, which is the long (q) arm of chromosome 22 at position 13.2

Molecular Location: base pairs 41,092,586 to 41,180,077 on chromosome 22 (Homo sapiens Annotation Release 109, GRCh38.p12) (NCBI)



Credit: Genome Decoration Page/NCBI

### Other Names for This Gene

- E1A-associated protein p300
- E1A-binding protein, 300kD
- EP300\_HUMAN
- p300
- p300 E1A-Associated Coactivator

## **Additional Information & Resources**

### Educational Resources

- Cancer Medicine (sixth edition, 2003): Chromosomal Abnormalities Involving Transcriptional Coactivators  
<https://www.ncbi.nlm.nih.gov/books/NBK12465/#A44443>
- Molecular Biology of the Cell (fourth edition, 2002): Eucaryotic Gene Regulatory Proteins Often Assemble into Complexes on DNA  
<https://www.ncbi.nlm.nih.gov/books/NBK26872/#A1300>

### Clinical Information from GeneReviews

- Rubinstein-Taybi Syndrome  
<https://www.ncbi.nlm.nih.gov/books/NBK1526>

### Scientific Articles on PubMed

- PubMed  
<https://www.ncbi.nlm.nih.gov/pubmed?term=%28%28EP300%5BTI%5D%29+OR+%28E1A+binding+protein+p300%5BTI%5D%29%29+OR+%28%28E1A-binding+protein,+300kD%5BTI%5D%29+OR+%28p300%5BTI%5D%29+OR+%28p300+E1A-Associated+Coactivator%5BTI%5D%29%29+AND+%28%28Genes%5BMH%5D%29+OR+%28Genetic+Phenomena%5BMH%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+720+days%22%5Bdp%5D>

### Catalog of Genes and Diseases from OMIM

- COLORECTAL CANCER  
<http://omim.org/entry/114500>
- E1A-BINDING PROTEIN, 300-KD  
<http://omim.org/entry/602700>
- LEUKEMIA, ACUTE MYELOID  
<http://omim.org/entry/601626>
- PROSTATE CANCER  
<http://omim.org/entry/176807>

### Research Resources

- Atlas of Genetics and Cytogenetics in Oncology and Haematology  
<http://atlasgeneticsoncology.org/Genes/P300ID97.html>
- ClinVar  
<https://www.ncbi.nlm.nih.gov/clinvar?term=EP300%5Bgene%5D>
- HGNC Gene Symbol Report  
[https://www.genenames.org/data/gene-symbol-report/#!/hgnc\\_id/HGNC:3373](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3373)

- Monarch Initiative  
<https://monarchinitiative.org/gene/NCBIGene:2033>
- NCBI Gene  
<https://www.ncbi.nlm.nih.gov/gene/2033>
- UniProt  
<https://www.uniprot.org/uniprot/Q09472>

## Sources for This Summary

- Bartholdi D, Roelfsema JH, Papadia F, Breuning MH, Niedrist D, Hennekam RC, Schinzel A, Peters DJ. Genetic heterogeneity in Rubinstein-Taybi syndrome: delineation of the phenotype of the first patients carrying mutations in EP300. *J Med Genet.* 2007 May;44(5):327-33. Epub 2007 Jan 12.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/17220215>  
*Free article on PubMed Central:* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597984/>
- Chaffanet M, Gressin L, Preudhomme C, Soenen-Cornu V, Birnbaum D, Pébusque MJ. MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). *Genes Chromosomes Cancer.* 2000 Jun; 28(2):138-44.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/10824998>
- Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ. p300 in prostate cancer proliferation and progression. *Cancer Res.* 2003 Nov 15;63(22):7638-40.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/14633682>
- Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, Daigo Y, Russell P, Wilson A, Sowter HM, Delhanty JD, Ponder BA, Kouzarides T, Caldas C. Mutations truncating the EP300 acetylase in human cancers. *Nat Genet.* 2000 Mar;24(3):300-3.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/10700188>
- Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. *Genes Dev.* 2000 Jul 1;14(13):1553-77. Review.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/10887150>
- Ida K, Kitabayashi I, Taki T, Taniwaki M, Noro K, Yamamoto M, Ohki M, Hayashi Y. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). *Blood.* 1997 Dec 15;90(12):4699-704.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/9389684>
- Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. *Oncogene.* 2004 May 24;23(24):4225-31. Review.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/15156177>
- Janknecht R. The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease. *Histol Histopathol.* 2002 Apr;17(2):657-68. Review.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/11962765>
- Kalkhoven E. CBP and p300: HATs for different occasions. *Biochem Pharmacol.* 2004 Sep 15; 68(6):1145-55. Review.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/15313412>

- Kitabayashi I, Aikawa Y, Yokoyama A, Hosoda F, Nagai M, Kakazu N, Abe T, Ohki M. Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. *Leukemia*. 2001 Jan;15(1):89-94.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/11243405>
  - Roelfsema JH, White SJ, Ariyürek Y, Bartholdi D, Niedrist D, Papadia F, Bacino CA, den Dunnen JT, van Ommen GJ, Breuning MH, Hennekam RC, Peters DJ. Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. *Am J Hum Genet*. 2005 Apr;76(4):572-80. Epub 2005 Feb 10.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/15706485>  
*Free article on PubMed Central:* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1199295/>
- 

Reprinted from Genetics Home Reference:  
<https://ghr.nlm.nih.gov/gene/EP300>

Reviewed: January 2007

Published: June 11, 2019

Lister Hill National Center for Biomedical Communications  
U.S. National Library of Medicine  
National Institutes of Health  
Department of Health & Human Services